MaxCyte (NASDAQ:MXCT – Get Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare MaxCyte to related companies based on the strength of its profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and earnings.
Earnings & Valuation
This table compares MaxCyte and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MaxCyte||$33.89 million||-$19.08 million||-27.47|
|MaxCyte Competitors||$2.80 billion||$101.15 million||13.51|
This table compares MaxCyte and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and price targets for MaxCyte and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Commercial physical research” companies have a potential upside of 40.87%. Given MaxCyte’s peers higher possible upside, analysts plainly believe MaxCyte has less favorable growth aspects than its peers.
Insider and Institutional Ownership
65.9% of MaxCyte shares are owned by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 5.4% of MaxCyte shares are owned by company insiders. Comparatively, 11.4% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
MaxCyte peers beat MaxCyte on 7 of the 12 factors compared.
About MaxCyte (Get Rating)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.